# A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Source: https://onco.cc/trials/nct02908906/  
OnCo record `nct02908906` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Cetrelimab in advanced solid tumours, run by Janssen Research & Development, LLC, active and no longer recruiting.

## Summary

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers is a phase 1/2 interventional study registered as NCT02908906 by Janssen Research & Development, LLC, with 234 participants enrolled, started 2016-11-21 and due to reach its primary completion in 2023-11-17. Interventions recorded: JNJ-63723283.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02908906
- Phase: 1/2
- Setting: 63723283LUC1001: A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancers
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 234

## Sources

- ClinicalTrials.gov NCT02908906: https://clinicaltrials.gov/study/NCT02908906

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Cetrelimab](https://onco.cc/drugs/cetrelimab/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct02908906.json